[HTML][HTML] Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an …
L Vikström, P Fjällström, YD Gwon… - The Lancet Regional …, 2023 - thelancet.com
Background To inform future preventive measures including repeated vaccinations, we have
searched for a clinically useful immune correlate of protection against fatal COVID-19 …
searched for a clinically useful immune correlate of protection against fatal COVID-19 …
[HTML][HTML] Weak humoral immune reactivity among residents of long-term care facilities following one dose of the BNT162b2 mRNA COVID-19 vaccine
MA Brockman, F Mwimanzi, Y Sang, K Ng, O Agafitei… - medRxiv, 2021 - ncbi.nlm.nih.gov
Background. Several Canadian provinces are extending the interval between COVID-19
vaccine doses to increase population vaccine coverage more rapidly. However …
vaccine doses to increase population vaccine coverage more rapidly. However …
Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities
M Trigueros, E Pradenas, D Palacín… - Age and …, 2022 - academic.oup.com
Background SARS-CoV-2 vaccination is the most effective strategy to protect older residents
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …
of long-term care facilities (LTCF) against severe COVID-19, but primary vaccine responses …
[HTML][HTML] Short-term safety of COVID-19 mRNA vaccines with respect to all-cause mortality in the older population in Norway
PLD Ruiz, N Gunnes, JM Gran, Ø Karlstad, R Selmer… - Vaccine, 2023 - Elsevier
Background There have been concerns about COVID-19 vaccination safety among frail
older individuals. We investigated the relationship between COVID-19 mRNA vaccination …
older individuals. We investigated the relationship between COVID-19 mRNA vaccination …
[HTML][HTML] Effectiveness of a fourth dose of mRNA COVID-19 vaccine against all-cause mortality in long-term care facility residents and in the oldest old: A nationwide …
P Nordström, M Ballin, A Nordström - The Lancet Regional Health …, 2022 - thelancet.com
Background The effect of a fourth dose of COVID-19 vaccine on the risk of death in the
oldest and frailest individuals is unknown. Methods Two matched cohorts were formed using …
oldest and frailest individuals is unknown. Methods Two matched cohorts were formed using …
Effectiveness and durability of a second COVID-19 booster against severe outcomes among older people in Norway: a population-based cohort study comparing …
M Stecher, AB Kristoffersen, K Lie… - International Journal …, 2023 - academic.oup.com
Background Evidence on the durability of the protection of a fourth dose of a monovalent or
bivalent messenger ribonucleic acid (mRNA) vaccine against coronavirus disease 2019 …
bivalent messenger ribonucleic acid (mRNA) vaccine against coronavirus disease 2019 …
[HTML][HTML] Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community …
Background The protective immunity against omicron following a BNT162b2 Pfizer booster
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
dose among elderly individuals (ie, those aged> 65 years) is not well characterised …
[HTML][HTML] Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish …
OS Søgaard, J Reekie, IS Johansen, H Nielsen… - Clinical Microbiology …, 2022 - Elsevier
Objectives To identify individual characteristics associated with serological COVID-19
vaccine responsiveness and the durability of vaccine-induced antibodies. Methods Adults …
vaccine responsiveness and the durability of vaccine-induced antibodies. Methods Adults …
COVID-19 outbreak in an elderly care home: very low vaccine effectiveness and late impact of booster vaccination campaign
CE van Ewijk, EI Hazelhorst, SJM Hahné, MJ Knol - Vaccine, 2022 - Elsevier
Background Elderly people in long-term care facilities (LTCF) are at higher risk for (severe)
COVID-19, yet evidence of vaccine effectiveness (VE) in this population is scarce. In …
COVID-19, yet evidence of vaccine effectiveness (VE) in this population is scarce. In …
[HTML][HTML] Effectiveness of vaccination against SARS-CoV-2 infection and Covid-19 hospitalisation among Finnish elderly and chronically ill—An interim analysis of a …
U Baum, E Poukka, AA Palmu, H Salo, TO Lehtonen… - PLoS …, 2021 - journals.plos.org
Background In Finland, both mRNA and adenovirus vector (AdV) Covid-19 vaccines have
been used after the vaccination campaign started on December 27, 2020. Vaccination of the …
been used after the vaccination campaign started on December 27, 2020. Vaccination of the …